In another phase I trial (Table 1), CD22 CAR T-cell therapy was evaluated in 58 patients with relapsed/refractory CD22+ malignancies (56 with B-ALL, one DLBCL and one chronic myeloid leukemia with ALL blast crisis). This evidence concerns the gene CD22 and diffuse large B-cell lymphoma.